CDK12 and neoplasm: Our recent work defined Cdk12 as a bona fide tumor suppressor gene—its ablation in the murine prostate epithelium is sufficient to induce preneoplastic lesions, while driving tumor progression in the setting of concomitant Trp53 loss (5).